History of PT-141 Research Peptide: From Melanotan II Discoveries to Modern Laboratory Applications
History of PT-141 Research Peptide: From Melanotan II Discoveries to Modern Laboratory Applications
Last Updated: January 15, 2025
Research Use Only Disclaimer: PT-141 (Bremelanotide) is sold exclusively for laboratory and preclinical research purposes. It is not intended for human or veterinary use, consumption, or self-administration. All information on this page is provided for scientific and educational reference only. Researchers must comply with all applicable federal, state, and local regulations governing the use of research peptides.
The story of PT-141 is one of the more compelling examples of how a serendipitous discovery in one area of peptide science can open an entirely unexpected research pathway. Understanding its history gives laboratory scientists important context for interpreting preclinical data, designing experiments, and recognizing why this compound occupies a unique position among melanocortin system research tools.
The Melanocortin System: Setting the Stage
Before PT-141 had a name, researchers were already deeply interested in the melanocortin system, a network of receptors (MC1R through MC5R) activated by peptide ligands derived from proopiomelanocortin (POMC). These receptors regulate a remarkably broad range of physiological processes in animal models, including pigmentation, energy balance, inflammation, and autonomic function.
The five melanocortin receptor subtypes each show distinct tissue expression patterns and pharmacological profiles. MC1R is predominantly expressed in melanocytes and plays a central role in pigmentation signaling. MC3R and MC4R are expressed in the central nervous system and have been the subject of extensive preclinical research related to energy homeostasis and autonomic pathways. Understanding how selective agonism or antagonism at each receptor subtype affects in vitro and in vivo outcomes became a major goal for peptide chemists through the 1980s and 1990s.
Alpha-MSH and the Early Melanocortin Peptide Research Era
The natural melanocortin peptides, particularly alpha-melanocyte-stimulating hormone (alpha-MSH), were characterized decades before PT-141 entered the research landscape. Alpha-MSH is a 13-amino acid peptide derived from POMC cleavage, and early research demonstrated its potent activation of melanocortin receptors in animal tissue preparations.
A key challenge with alpha-MSH in research settings was its short half-life. Like many endogenous peptides, it was rapidly degraded by enzymatic activity in biological samples. This pharmacokinetic limitation prompted peptide chemists to explore structural modifications that could extend stability without eliminating receptor binding affinity.
This line of inquiry gave rise to a generation of synthetic melanocortin analogs that would eventually lead to the Melanotan compounds and, downstream, to PT-141 itself.
The University of Arizona and the Melanotan Research Program
Much of the foundational work that produced PT-141 traces back to a research program at the University of Arizona, where investigators were exploring the pharmacology of melanocortin peptides in the context of pigmentation biology. The research group, led in part by Dr. Victor Hruby, had longstanding expertise in peptide synthesis and structure-activity relationship (SAR) analysis.
The goal of the early Melanotan research program was to develop alpha-MSH analogs with improved receptor binding characteristics and longer metabolic stability compared to the native peptide. Melanotan I (afamelanotide) was one of the early compounds to emerge from this program. It incorporated structural modifications, including a lactam bridge and substitutions at key residues, that enhanced metabolic resistance and melanocortin receptor affinity.
Melanotan II (MT-II) followed as a further-modified cyclic heptapeptide. Its structural compactness gave it enhanced potency at melanocortin receptors, and it became a widely used tool compound in preclinical melanocortin system research. MT-II's pharmacology proved to be notably nonselective across receptor subtypes, which made it a useful probe for exploring the broader melanocortin system but also complicated interpretation of subtype-specific effects.
From Melanotan II to PT-141: The Structural Transition
The transition from MT-II to PT-141 represents a meaningful chapter in the SAR history of melanocortin peptides. During preclinical and early phase research with Melanotan compounds, researchers noted that some observed biological signals in animal models appeared to involve receptor pathways distinct from those driving pigmentation responses.
This observation prompted further structural modification work. PT-141, also known by its INN Bremelanotide, is structurally derived from MT-II. The primary chemical distinction involves the removal of the MT-II N-terminal acetyl group combined with other modifications resulting in a linear, then cyclized peptide with altered receptor binding kinetics relative to its parent compound.
The amino acid sequence of PT-141 is: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH (variations in reporting exist in the literature depending on specific synthesis protocols). Its cyclic lactam structure contributes to conformational rigidity that influences receptor binding selectivity and metabolic stability compared to linear melanocortin peptides.
PT-141 in Preclinical Research: A Timeline Overview
The following table summarizes key milestones in PT-141 research history from a scientific literature perspective:
| Period | Research Focus | Key Developments |
|---|---|---|
| Late 1980s | Alpha-MSH analog synthesis | Foundational SAR work on melanocortin peptides at U of AZ |
| Early 1990s | Melanotan I and II synthesis | MT-I and MT-II characterized as potent, stable melanocortin agonists |
| Mid 1990s | MT-II preclinical studies | Broad receptor pharmacology explored in animal models |
| Late 1990s | PT-141 structural derivation | Bremelanotide synthesized as MT-II structural derivative |
| Early 2000s | Melanocortin receptor selectivity studies | MC3R/MC4R pathway research intensifies using PT-141 as tool compound |
| 2010s | Continued preclinical investigation | PT-141 used in receptor binding assays and CNS receptor mapping studies |
Receptor Pharmacology Research: What the Preclinical Literature Covers
One reason PT-141 has remained a relevant research compound over decades is its pharmacological profile at melanocortin receptor subtypes. Unlike MT-II, which shows potent activity across multiple receptor subtypes, PT-141 has been studied for its relative selectivity profile at MC3R and MC4R in in vitro assay systems.
MC4R, in particular, has attracted significant research interest due to its expression in hypothalamic and limbic brain regions in animal models. Preclinical radioligand binding studies and in vitro functional assays have used PT-141 as a reference compound to characterize the pharmacological properties of the MC4R binding site.
This receptor-level research does not support any specific clinical conclusions. Rather, it has helped build a more detailed picture of melanocortin receptor pharmacology, ligand-receptor interaction kinetics, and the structural requirements for receptor activation in cell-free and cell-based systems.
PT-141 as a Reference Compound in Melanocortin Research
In modern laboratory applications, PT-141 (Bremelanotide) continues to serve several functions as a research tool compound:
Receptor Binding Reference: PT-141 is used in competitive radioligand binding assays to characterize the affinity and kinetics of novel melanocortin receptor ligands. Its well-characterized binding profile at MC3R and MC4R makes it a useful comparator in binding competition experiments.
In Vitro Cell-Based Assays: Researchers use PT-141 to activate melanocortin receptors in transfected cell lines, measuring downstream second messenger signaling (cyclic AMP, beta-arrestin recruitment) to study receptor activation pathways.
SAR Studies: PT-141's structure provides a scaffold for comparative SAR research, allowing chemists to explore how structural modifications to the cyclic lactam template affect receptor selectivity and binding kinetics.
Comparative Pharmacology: Because both MT-II and PT-141 are available as research-grade standards, they are frequently used as paired comparison compounds in assays designed to investigate structure-activity differences within the cyclic melanocortin peptide scaffold.
The Peptide Chemistry Context: Why Structure Shapes Research Value
To understand why PT-141's history matters to the working laboratory scientist, it helps to appreciate what the structural evolution from alpha-MSH to MT-II to PT-141 actually changed at the molecular level.
Alpha-MSH is a linear tridecapeptide. Its flexibility in solution means it can adopt multiple conformations when approaching a receptor binding site, which affects both potency and selectivity. Synthetic analogs that introduce conformational constraints, such as cyclic lactam bridges or D-amino acid substitutions, restrict the peptide's conformational space and often improve receptor binding potency and selectivity.
PT-141's cyclic structure is a direct product of this strategy. The lactam bridge between the epsilon-amino group of the lysine residue and the carboxyl group of the aspartate residue enforces a specific backbone geometry. The incorporation of D-phenylalanine at a key position further modifies the peptide's binding orientation. The net result is a compound with distinct receptor pharmacology compared to both alpha-MSH and MT-II.
For researchers designing binding assays or cell-based functional studies, this structural context is directly relevant to experimental interpretation.
Regulatory and Research Compliance Context
It is important for researchers sourcing PT-141 to understand where it sits in the regulatory landscape. PT-141 (Bremelanotide) is not approved as an active pharmaceutical ingredient (API) for any research use without appropriate institutional oversight in the United States. Research institutions conducting experiments with PT-141 must maintain appropriate documentation and comply with institutional policies governing the use of research chemicals.
Palmetto Peptides supplies PT-141 exclusively as a research peptide for use in qualified laboratory settings. All products come with a Certificate of Analysis (COA) confirming purity and identity. Purchasers are responsible for ensuring that their use of this compound complies with all applicable regulations.
See our article on Legal and Regulatory Considerations for Buying PT-141 and Other Research Peptides in the US for a full discussion of the compliance framework.
Related Research Resources in This Cluster
- Palmetto Peptides Guide to the Research Peptide PT-141 (Bremelanotide)
- PT-141 Chemical Structure, Sequence, and Molecular Properties for Research Use
- PT-141 Mechanism of Action as a Melanocortin Receptor Agonist in Preclinical Research
- PT-141 vs Melanotan II: Comparative Analysis for Research Peptide Applications
- Ensuring Purity and Quality When Purchasing PT-141 Research Peptides: What to Look For
- PT-141 Structure-Activity Relationships: How Molecular Modifications Affect Melanocortin Receptor Research Outcomes
Frequently Asked Questions
Q: What is the origin of PT-141 as a research compound? PT-141 (Bremelanotide) was derived from Melanotan II (MT-II), a cyclic melanocortin peptide analog originally developed at the University of Arizona. Structural modifications to MT-II produced PT-141, which has a distinct receptor pharmacology profile used in preclinical melanocortin receptor research.
Q: How does PT-141 differ structurally from Melanotan II? PT-141 is structurally derived from MT-II with modifications affecting N-terminal chemistry and overall receptor binding profile. Both compounds share a cyclic lactam scaffold, but distinct structural features result in different receptor selectivity at melanocortin receptor subtypes in vitro.
Q: What melanocortin receptors does PT-141 interact with in research settings? In preclinical research, PT-141 has been characterized primarily as an agonist at MC3R and MC4R subtypes. It has been used in radioligand binding assays and cell-based functional studies to probe these receptor subtypes in vitro.
Q: Is PT-141 approved for human use? PT-141 as supplied by Palmetto Peptides is a research-grade compound intended exclusively for laboratory and preclinical use. It is not sold or intended for human or veterinary administration.
Q: Why is the history of PT-141 relevant to laboratory researchers? Understanding PT-141's developmental history from alpha-MSH analogs through Melanotan I and II to Bremelanotide provides essential context for interpreting its receptor pharmacology, designing appropriate control experiments, and placing published preclinical data in its proper scientific framework.
Citations
Hadley ME, Dorr RT. "Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization." Peptides. 2006;27(4):921-930. PubMed
Hruby VJ, Lu D, Sharma SD, et al. "Cyclic lactam alpha-melanotropin analogues of Ac-Nle4-cyclo[Asp5,D-Phe7,Lys10] alpha-MSH-(4-10)-NH2 with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors." Journal of Medicinal Chemistry. 1995;38(18):3454-3461.
Wikberg JE. "Melanocortin receptors: new opportunities in drug discovery." Expert Opinion on Therapeutic Patents. 2001;11(1):61-76.
Cone RD. "Studies on the physiological functions of the melanocortin system." Endocrine Reviews. 2006;27(7):736-749. PubMed
Dorr RT, Lines R, Levine N, et al. "Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study." Life Sciences. 1996;58(20):1777-1784.
Author: Palmetto Peptides Research Team
This article is intended for educational and scientific reference purposes only. PT-141 is a research peptide sold exclusively for laboratory use. It is not intended for human or veterinary use, diagnosis, treatment, or prevention of any condition. Always consult institutional guidelines and applicable regulations before conducting research with this compound.